Ocular Therapeutix (NASDAQ:OCUL) Lowered to Strong Sell at Zacks Investment Research

Ocular Therapeutix (NASDAQ:OCUL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using […]

Related Keywords

Bedford ,Massachusetts ,United States ,Switzerland ,Swiss , ,Morgan Stanley ,Zacks Investment Research ,Swiss National Bank ,Ocular Therapeutix Company Profile Get Rating ,Ocular Therapeutix Inc ,Sg Americas Securities ,Raymond James Associates ,Mission Capital ,Ocular Therapeutix ,Get Rating ,Summer Road Llc ,National Bank ,Therapeutix Company Profile ,Resure Sealant ,Nasdaq Ocul ,Hocul ,Medical ,Downgrade ,